Although this needs to be confirmed in future in vivo studies, administration of a GPX4 inhibitor after combination treatment with EGFR‐ or FGFR‐TKIs plus alectinib would be a reasonable rationale to enhance tolerability without compromising efficacy and would be a useful therapeutic option for overcoming acquired resistance to targeted TKI alone through inhibiting the emergence of DTP cells in ALK+ NSCLC. The gene discussed is GPX4; the disease is non-small cell lung carcinoma.